A federal advisory committee voted narrowly on Tuesday to back the compounding of two specific peptides, citing preliminary observational data suggesting a strong correlation with the Health Secretary's deltoids.
A federal advisory committee voted narrowly on Tuesday to back the compounding of two specific peptides, citing preliminary observational data suggesting a strong correlation with Robert F. Kennedy Jr.’s overall vascularity.
The panel declined to recommend a third amino acid chain, warning that more research is needed to determine whether the compound is safe for the general population or strictly indicated for septuagenarian politicians attempting to deadlift in denim. Experts caution that the longitudinal data, which is currently limited to Kennedy’s own podcast appearances, remains entirely self-reported and lacks a control group.
While a cohort of one prominent political figure is not traditionally considered a double-blind clinical trial, the preliminary visual evidence suggests the protocol is at least associated with a very specific type of taut, leathery vitality.
The updated FDA guidance arrives amid a surge in off-label peptide compounding among wellness influencers. While a recent JAMA paper indicated the compounds may play a minor role in tissue repair, public health officials stressed that the difference between association and causation is critical when evaluating a regimen that concurrently involves raw milk consumption and bare-chested falconry.
The NIH is expected to formally review the panel's findings next month, though researchers warn that any peer-reviewed conclusions may be inherently compromised by the methodological difficulty of regulating a test subject who oversees the nation's medical agencies.